Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner.
about
Use of preclinical models to improve treatment of retinoblastoma.Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest.HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progressionThe retinoblastoma protein binds to a family of E2F transcription factorsReversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivationGenetic characterization of a mammalian protein-protein interaction domain by using a yeast reverse two-hybrid systemRegulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinasesExpression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entryCyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylationSequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinaseDP-2, a heterodimeric partner of E2F: identification and characterization of DP-2 proteins expressed in vivoE2F activity is regulated by cell cycle-dependent changes in subcellular localizationInduction of S-phase entry by E2F transcription factors depends on their nuclear localizationSpecific regulation of E2F family members by cyclin-dependent kinasesAlpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrestId2 specifically alters regulation of the cell cycle by tumor suppressor proteinsE2F-4 switches from p130 to p107 and pRB in response to cell cycle reentryAssociation of p107 with Sp1: genetically separable regions of p107 are involved in regulation of E2F- and Sp1-dependent transcriptionDifferential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteinsE2F-5, a new E2F family member that interacts with p130 in vivoIn vivo association of E2F and DP family proteinsAnalysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F-1Deregulated E2F transcriptional activity in autonomously growing melanoma cellsThe retinoblastoma family: twins or distant cousins?Role of APC and DNA mismatch repair genes in the development of colorectal cancers.Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F functionCyclin-dependent kinase 11(p58) interacts with HBO1 and enhances its histone acetyltransferase activityCyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcriptionCyclins and cyclin-dependent kinases: a biochemical viewp130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activityRetinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexesNon-dependence of cyclin E/Cdk2 kinase activity on the initiation of oocyte maturation in goldfish.Physical and functional interaction of HIV-1 Tat with E2F-4, a transcriptional regulator of mammalian cell cycle.Exploring the functional complexity of cellular proteins by protein knockoutCell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F siteGrowth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket.Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor.Dysregulation of cyclin E gene expression in human cytomegalovirus-infected cells requires viral early gene expression and is associated with changes in the Rb-related protein p130.p107 in the public eye: an Rb understudy and more.
P2860
Q21144714-3134173C-DAEC-4C1C-A9B0-6E1E2EA30B59Q22008677-9E4B3F90-A603-4069-AD19-9FBAC0B42E54Q24307735-1D65CECA-12CD-44CE-A6A8-C882766E453DQ24320199-D764D9D5-6F83-4775-8318-356ADEDC0639Q24537209-EAB8E583-5A68-444C-ACD7-8DFF8A6A83FDQ24568291-D013C6A8-F5E9-4D4C-B8E1-9B45D84C5C5AQ24596103-88557A74-0E37-4B6D-BDC4-71B9CEE638C4Q24602450-428AA4B0-F3E7-48DB-B425-D2E6B25F7083Q24607291-E7E6369D-E986-4826-8F1D-F5908B6FA81DQ24607335-A58210B0-40E3-4F42-A2CE-AAC1C098A107Q24610717-14C1C8F6-5781-4AB9-9472-FE13683D9BC3Q24622928-4997DE9E-8481-4032-AFC9-2E83C6AE1660Q24643965-6D29E1E5-A3F8-432D-815A-AD34604E97E7Q24644652-4C37A838-5BA4-46D0-88D9-C755803CB013Q24646032-A5AAA2DD-8552-4037-8713-D7D64AFF14BFQ24648859-809ACC63-603D-46B8-B8FB-8FD605694EE0Q24649133-C139ABF5-5C9B-456F-B71D-8E355B6A2C2DQ24650515-6F808120-1A86-4F1A-9091-C44F517E1DCEQ24651154-FC7B4C78-2D27-4F30-92CA-A597C7AF3507Q24651899-61E94080-0948-43E3-8C4A-94A06E3124B5Q24652329-6E1CC97A-8A00-4A70-9660-DFAA6C959BCDQ24652555-5EBD77F0-E56B-4BBE-BADD-49E51FD0AA47Q24655699-D6F32CE3-3548-414E-8B7F-C3044E9FE9C8Q24676546-F98907D9-0802-4E97-832F-B83DE582563DQ24792893-3466E4EB-FB2A-4BBF-8AC6-86B301D94311Q24806345-AD47872E-C115-44BC-85DE-E1DA0AC60775Q28137829-16FC0002-626E-4B97-822E-2BFE398B22F5Q28257262-7C49B69C-0C1A-40D2-B2DF-97480437A405Q28295915-CB217807-366E-4551-ABC1-CA5C21830BA5Q28611449-24181EC2-3388-4B57-BE8F-797E36E42B9EQ28647314-BA556E23-4E7E-4A8C-954A-40EBDDB07BBEQ28647334-676D82AE-B2A1-4D68-908C-1D72854F4ADFQ30887957-BC533B80-5644-4A9F-8677-EE258D2ACA3BQ31072762-725EBA9D-C36C-44C8-838E-3A140B8F25F9Q33715456-19ECC8EA-3161-4B0D-8BF6-17A60A9C00FBQ33769566-D678DC2D-F6BF-4FF5-955D-6880849732F8Q33774923-B644B8F7-BE31-4E09-8BBD-16C16D5829F8Q33778594-616618C7-CEE8-431B-B160-E140D412BCC0Q33803614-D39281B7-1367-40A5-9E51-37586DCF5FEEQ33818607-C53FE87B-F8C1-4051-A1E6-0CA8A262F558
P2860
Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Cyclin E/cdk2 and cyclin A/cdk ...... a temporally distinct manner.
@en
type
label
Cyclin E/cdk2 and cyclin A/cdk ...... a temporally distinct manner.
@en
prefLabel
Cyclin E/cdk2 and cyclin A/cdk ...... a temporally distinct manner.
@en
P2093
P356
P1433
P1476
Cyclin E/cdk2 and cyclin A/cdk ...... a temporally distinct manner.
@en
P2093
P304
P356
10.1101/GAD.6.10.1874
P577
1992-10-01T00:00:00Z